Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 November 2015

Ten medicines, including a first-in-class orphan medicine for narcolepsy, recommended for authorisation in the EU

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended ten medicines for marketing authorisation at its November 2015 meeting.

The CHMP recommended granting a marketing authorisation for Wakix (pitolisant) for the treatment of narcolepsy. Narcolepsy is a rare, long-term sleep disorder which affects the brain's ability to regulate the normal sleep-wake cycle, and may occur with or without cataplexy (sudden severe muscle weakness or loss of muscle control). Wakix, a first-in-class medicine, has an orphan designation. For more information, please see the press release in the grid below.

The CHMP recommended granting a marketing authorisation for two blood cancer medicines: Oncaspar (pegaspargase) and Spectrila (asparaginase), both for the treatment of acute lymphoblastic leukaemia. Spectrila has an orphan designation.

Benepali (etanercept), a biosimilar, received a positive opinion for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and plaque psoriasis.

Briviact (brivaracetam) was recommended for marketing authorisation by the Committee for the treatment of partial-onset epilepsy seizures.

The CHMP recommended granting a marketing authorisation to Episalvan for the treatment of partial thickness wounds in adults. The active substance of Episalvan is birch bark extract.

Three generic medicines received positive opinions from the Committee: Pemetrexed Accord (pemetrexed) for the treatment of unresectable malignant pleural mesothelioma and locally advanced or metastatic non-small cell lung cancer, Lopinavir / Ritonavir Mylan (lopinavir / ritonavir) for the treatment of human immunodeficiency virus (HIV) infection in adults, adolescents and children above the age of two years and Eptifibatide Accord (eptifibatide) for the prevention of early myocardial infarction.

One hybrid medicine, Pemetrexed Actavis (pemetrexed), received a positive opinion for the treatment of unresectable malignant pleural mesothelioma and locally advanced or metastatic non-small cell lung cancer. Hybrid applications rely in part on the results of studies carried out with a reference product and in part on new data.

Negative opinion on new medicine

The CHMP adopted a negative opinion for Solumarv (insulin human) which was expected to be used to treat patients with diabetes who require insulin to control their blood sugar levels. Solumarv was developed as a biosimilar medicine. For more information, please see the questions-and-answers document in the grid below.

Three recommendations on extensions of therapeutic indication

The Committee recommended extensions of indication for Cimzia and Zutectra.

The Committee also recommended extending the use of Pyramax, an artemisinin combination therapy for malaria which was first evaluated in 2012 under EMA's Article 58 programme. This allows the CHMP to assess and give a scientific opinion in cooperation with the World Health Organization (WHO) for medicines intended exclusively for markets outside the European Union (EU). Through this mechanism, regulators outside the EU can use the CHMP assessment as part of their national authorisation process.

Pyramax is currently available as a film-coated tablet to treat malaria caused by P. falciparum and P. vivax in adults and children over 20 kg. These species of the malaria parasite account for the majority of cases.

The CHMP recommends to add a new pharmaceutical form, granules for oral suspension, and to extend the use of Pyramax in this formulation to children and infants weighing 5 kg to less than 20 kg. This provides an age-appropriate formulation for very small children.

The CHMP also recommended an extension of the indication for Pyramax to remove restrictions on repeated courses of treatment in patients and on its use only in areas of low malaria transmission with evidence of artemisinin resistance.

Outcome of review of human papillomavirus (HPV) vaccines

The CHMP has completed the review of the evidence surrounding reports of two syndromes, complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome (POTS) in young women given human papillomavirus (HPV) vaccines. After due consideration, the CHMP confirmed the recent recommendation from EMA's Pharmacovigilance Risk Assessment Committee (PRAC) that the available evidence does not support a causal link between the vaccines and development of CRPS or POTS. Please refer to the public health communication in the grid below for more information.

Agenda and minutes

The agenda of the November 2015 meeting is published on EMA's website. Minutes of the October 2015 CHMP meeting will be published next week.

CHMP statistics

Key figures from the November 2015 CHMP meeting are represented in the graphic below.

More information on this, and all other outcomes of the CHMP's November 2015 meeting, is available in the grid below.

Positive recommendations on new medicines

Name of medicine	Benepali
International non-proprietary name (INN)	etanercept
Marketing-authorisation applicant	Samsung Bioepis UK Limited (SBUK)
Therapeutic indication	Treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and plaque psoriasis
More information	Summary of opinion for Benepali

Name of medicine	Briviact
International non-proprietary name (INN)	brivaracetam
Marketing-authorisation applicant	UCB Pharma SA
Therapeutic indication	Treatment of partial-onset seizures
More information	Summary of opinion for Briviact

Name of medicine	Episalvan
International non-proprietary name (INN)	birch bark extract
Marketing-authorisation applicant	Birken AG
Therapeutic indication	Treatment of partial thickness wounds
More information	Summary of opinion for Episalvan

Name of medicine	Oncaspar
International non-proprietary name (INN)	pegaspargase
Marketing-authorisation applicant	Baxalta Innovations GmbH
Therapeutic indication	Treatment of acute lymphoblastic leukaemia
More information	Summary of opinion for Oncaspar

Name of medicine	Spectrila
International non-proprietary name (INN)	asparaginase
Marketing-authorisation applicant	medac Gesellschaft fuer klinische Spezialpraeparate mbH
Therapeutic indication	Treatment of acute lymphoblastic leukaemia
More information	Summary of opinion for Spectrila

Positive recommendations on new generic medicines

Name of medicine	Eptifibatide Accord
International non-proprietary name (INN)	eptifibatide
Marketing-authorisation applicant	Accord Healthcare Limited
Therapeutic indication	Prevention of early myocardial infarction
More information	Summary of opinion for Eptifibatide Accord

Name of medicine	Lopinavir / Ritonavir Mylan
International non-proprietary name (INN)	lopinavir / ritonavir
Marketing-authorisation applicant	Mylan S.A.S.
Therapeutic indication	Treatment of HIV infection in adults, adolescents and children above the age of 2 years
More information	Summary of opinion for Lopinavir / Ritonavir Mylan

Name of medicine	Pemetrexed Accord
International non-proprietary name (INN)	pemetrexed
Marketing-authorisation applicant	Accord Healthcare Ltd
Therapeutic indication	Treatment of unresectable malignant pleural mesothelioma and locally advanced or metastatic non-small cell lung cancer
More information	Summary of opinion for Pemetrexed Accord

Positive recommendation on new hybrid medicine

Name of medicine	Pemetrexed Actavis
International non-proprietary name (INN)	pemetrexed
Marketing-authorisation applicant	Actavis Group PTC ehf
Therapeutic indication	Treatment of unresectable malignant pleural mesothelioma and locally advanced or metastatic non-small cell lung cancer
More information	Summary of opinion for Pemetrexed Actavis

Negative recommendation on new medicine

Name of medicine	Solumarv
International non-proprietary name (INN)	insulin human
Marketing-authorisation applicant	Marvel Life Sciences Ltd
Therapeutic indication	Treatment of diabetes
More information	Questions and answers on Solumarv

Positive recommendations on extensions of therapeutic indications

Name of medicine	Cimzia
INN	certolizumab pegol
Marketing-authorisation holder	UCB Pharma SA
More information	Summary of opinion for Cimzia

Name of medicine	Zutectra
INN	human hepatitis b immunoglobulin
Marketing-authorisation holder	Biotest Pharma GmbH
More information	Summary of opinion for Zutectra

Public health recommendation

Other updates

Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures

Opinions on safety variations

Start of Community reviews

Scientific advice and protocol assistance

Guidelines and concept papers adopted

Overview of invented names reviewed in September 2015 by the Name Review Group (NRG)

Organisational matters